CureVac Financial Statements From 2010 to 2026

CVAC Stock  USD 4.52  0.04  0.89%   
CureVac NV's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CureVac NV's valuation are provided below:
Gross Profit
66 M
Profit Margin
1.8211
Market Capitalization
B
Enterprise Value Revenue
6.252
Revenue
70.7 M
We have found one hundred twenty available fundamental signals for CureVac NV, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of CureVac NV's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 1, 2026, Market Cap is expected to decline to about 701.9 M. In addition to that, Enterprise Value is expected to decline to about 281.3 M

CureVac NV Total Revenue

561.94 Million

Check CureVac NV financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CureVac NV's main balance sheet or income statement drivers, such as Tax Provision of 30.1 M, Net Interest Income of 13 M or Interest Income of 7 M, as well as many indicators such as Price To Sales Ratio of 1.31, Dividend Yield of 0.0 or PTB Ratio of 1.01. CureVac financial statements analysis is a perfect complement when working with CureVac NV Valuation or Volatility modules.
  
Build AI portfolio with CureVac Stock
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.

CureVac NV Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets845 M802.8 M451.7 M
Slightly volatile
Short and Long Term Debt Total41 M39 M18.9 M
Slightly volatile
Other Current Liabilities29.9 M31.5 M34.6 M
Slightly volatile
Total Current Liabilities68.7 M72.3 M85.6 M
Slightly volatile
Other Liabilities198.2 M99.6 M107.2 M
Slightly volatile
Property Plant And Equipment Net185.8 M244.7 M108.3 M
Slightly volatile
Current Deferred Revenue56.5 M51.3 M28.9 M
Slightly volatile
Accounts Payable16.4 M17.3 M23.5 M
Slightly volatile
Cash560.4 M481.7 M268.6 M
Slightly volatile
Non Current Assets Total208.8 M276.4 M122.4 M
Slightly volatile
Non Currrent Assets Other1.3 M1.5 M590.1 K
Slightly volatile
Other Assets95010004.9 M
Slightly volatile
Cash And Short Term Investments569.6 M485.4 M292.5 M
Slightly volatile
Net Receivables25.3 M32.9 M15.1 M
Slightly volatile
Common Stock Total Equity26.1 M24.9 M9.1 M
Slightly volatile
Common Stock Shares Outstanding206.8 M225.3 M183.2 M
Slightly volatile
Short Term Investments6.7 M3.6 M23.7 M
Slightly volatile
Liabilities And Stockholders Equity845 M802.8 M451.7 M
Slightly volatile
Non Current Liabilities Total32.2 M33.9 M107.5 M
Pretty Stable
Inventory514 K541 K9.6 M
Slightly volatile
Other Current Assets7.2 M7.6 M8.2 M
Slightly volatile
Total Liabilities100.9 M106.2 M193.2 M
Slightly volatile
Deferred Long Term Liabilities258.2 K271.8 K649.4 K
Slightly volatile
Net Invested Capital503 M696.6 M247.5 M
Slightly volatile
Property Plant And Equipment Gross210.3 M323.2 M117 M
Slightly volatile
Total Current Assets636.3 M526.4 M329.4 M
Slightly volatile
Accumulated Other Comprehensive Income1.6 B2.1 B941.9 M
Slightly volatile
Capital Stock19.3 M26.9 M9.2 M
Slightly volatile
Non Current Liabilities Other16.2 K17.1 K557.2 K
Slightly volatile
Net Working Capital467.1 M454.1 M237.4 M
Slightly volatile
Short Term Debt3.8 M5.3 M1.9 M
Slightly volatile
Intangible Assets13.7 M12.7 M9.4 M
Slightly volatile
Common Stock19.3 M26.9 M9.2 M
Slightly volatile
Property Plant Equipment242 M230.5 M100 M
Slightly volatile
Long Term Debt52 M58.5 M63.8 M
Slightly volatile

CureVac NV Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest IncomeM12.4 M4.2 M
Slightly volatile
Depreciation And Amortization19.9 M18.8 M11.1 M
Slightly volatile
Selling General Administrative67.5 M69.7 M41.3 M
Slightly volatile
Selling And Marketing Expenses4.7 M4.4 M1.5 M
Slightly volatile
Total Revenue561.9 M535.2 M94 M
Slightly volatile
Other Operating Expenses295.5 M357.5 M178.8 M
Slightly volatile
Research Development211.5 M153 M118.2 M
Slightly volatile
Cost Of Revenue111.9 M105.8 M60.4 M
Slightly volatile
Total Operating Expenses185.8 M251.7 M119.5 M
Slightly volatile
Reconciled Depreciation15.3 M18.8 MM
Slightly volatile

CureVac NV Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow500.3 M402.5 M280.1 M
Slightly volatile
Depreciation16.2 M18.8 M9.4 M
Slightly volatile
Capital Expenditures17.5 M18.4 M31.5 M
Slightly volatile
End Period Cash Flow560.4 M481.7 M268.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.311.3806425
Slightly volatile
Days Sales Outstanding21.3222.4396167
Slightly volatile
Capex To Depreciation0.930.98063.5967
Slightly volatile
EV To Sales0.530.5533421
Slightly volatile
Inventory Turnover20519629.8469
Slightly volatile
Days Of Inventory On Hand1.771.865975.7154
Very volatile
Payables Turnover6.436.12722.7207
Slightly volatile
Sales General And Administrative To Revenue0.120.13011.3405
Slightly volatile
Research And Ddevelopement To Revenue0.270.28592.8464
Slightly volatile
Capex To Revenue0.03270.03450.9802
Slightly volatile
Cash Per Share2.462.16321.6745
Slightly volatile
Days Payables Outstanding56.5959.5704173
Pretty Stable
Intangibles To Total Assets0.03430.03130.0405
Slightly volatile
Current Ratio7.647.27613.4297
Slightly volatile
Receivables Turnover17.0816.26595.5536
Slightly volatile
Graham Number5.696.46.9732
Slightly volatile
Capex Per Share0.07810.08220.173
Slightly volatile
Revenue Per Share2.52.38520.4475
Slightly volatile
Interest Debt Per Share0.260.17370.1207
Slightly volatile
Debt To Assets0.04610.04850.0533
Pretty Stable
Operating Cycle23.0924.3055243
Slightly volatile
Days Of Payables Outstanding56.5959.5704173
Pretty Stable
Ebt Per Ebit0.811.07430.9797
Very volatile
Long Term Debt To Capitalization2.342.632.8714
Slightly volatile
Total Debt To Capitalization0.05030.0530.1582
Pretty Stable
Quick Ratio7.637.26873.3244
Slightly volatile
Net Income Per E B T1.080.84970.9959
Pretty Stable
Cash Ratio6.996.65882.1577
Slightly volatile
Days Of Inventory Outstanding1.771.865975.7154
Very volatile
Days Of Sales Outstanding21.3222.4396167
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.220.81891.1614
Slightly volatile
Fixed Asset Turnover2.32.18750.5467
Slightly volatile
Debt Ratio0.04610.04850.0533
Pretty Stable
Price Sales Ratio1.311.3806425
Slightly volatile
Asset Turnover0.70.66660.1681
Slightly volatile

CureVac NV Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap701.9 M738.9 M6.5 B
Slightly volatile
Enterprise Value281.3 M296.1 M6.3 B
Slightly volatile

CureVac Fundamental Market Drivers

Forward Price Earnings5.2356
Cash And Short Term Investments485.4 M

CureVac Upcoming Events

23rd of April 2024
Upcoming Quarterly Report
View
4th of June 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
23rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CureVac NV Financial Statements

CureVac NV stakeholders use historical fundamental indicators, such as CureVac NV's revenue or net income, to determine how well the company is positioned to perform in the future. Although CureVac NV investors may analyze each financial statement separately, they are all interrelated. For example, changes in CureVac NV's assets and liabilities are reflected in the revenues and expenses on CureVac NV's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CureVac NV. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue51.3 M56.5 M
Total Revenue535.2 M561.9 M
Cost Of Revenue105.8 M111.9 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.13  0.12 
Research And Ddevelopement To Revenue 0.29  0.27 
Capex To Revenue 0.03  0.03 
Revenue Per Share 2.39  2.50 
Ebit Per Revenue 0.33  0.35 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:
Check out the analysis of CureVac NV Correlation against competitors.
For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.24
Earnings Share
0.67
Revenue Per Share
0.44
Quarterly Revenue Growth
(0.89)
Return On Assets
0.2377
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.